Characterization of mild whole-body hyperthermia protocols using human breast, ovarian, and colon tumors grown in severe combined immunodeficient mice
/in Colorectal Cancer, Hyperthermia, International Publications /von 1999-01-01 / Infect Dis Obstet Gynecol 1999;7(1-2):91-7Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus
/in International Publications, Newcastle Disease Virus /von 1999-01-01 / Gene Ther. 1999 Jan;6(1):63-73A pilot study of melphalan, tumor necrosis factor-alpha and 41.8 degrees C whole-body hyperthermia
/in Hyperthermia, International Publications /von 1999-01-01 / Cancer Chemother. Pharmacol. 1999;43(5):409-14
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution